New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 25, 2014
05:35 EDTAMGN, BAYRYBayer, Onyx reports NEXAVAR Phase 3 trial did not meet primary endpoint
Bayer HealthCare (BAYRY) and Onyx Pharmaceuticals, an Amgen subsidiary (AMGN), announced that an investigational Phase 3 trial of NEXAVAR tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival. The study, called RESILIENCE, evaluated the efficacy and safety of sorafenib in combination with capecitabine, an oral chemotherapeutic agent, compared to placebo plus capecitabine, in patients with HER2-negative breast cancer who are resistant to or have failed prior taxane therapy, and resistant to or failed anthracycline or for whom further anthracycline therapy is not indicated. Based on initial review of the data, the types of adverse events observed were generally comparable with those known for either sorafenib or capecitabine. Data from this study are expected to be presented at an upcoming scientific congress.
News For BAYRY;AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
09:02 EDTAMGNAmgen says FDA grants priority review for Kyprolis sNDA
Subscribe for More Information
March 27, 2015
15:40 EDTBAYRYPanasonic Healthcare may bid for Bayer's blood glucose meter unit, Nikkei says
Subscribe for More Information
March 26, 2015
11:13 EDTBAYRYBofA/Merrill European pharma analyst holds an analyst/industry conference call
Subscribe for More Information
10:04 EDTBAYRYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:45 EDTAMGNBiotech valuation concerns 'misguided,' says Piper Jaffray
Subscribe for More Information
05:31 EDTBAYRYBayer downgraded to Neutral from Buy at UBS
Subscribe for More Information
March 25, 2015
07:17 EDTBAYRYSociety for Reproductive Investigation to hold scientific meeting
62nd Annual Scientific Meeting: SRI 2015 is being held in San Francisco on March 25-28.
March 24, 2015
09:10 EDTAMGNDako announces collaboration agreement with Amgen
Dako, an Agilent Technologies (A) company, announced a new Master Collaboration Agreement with Amgen (AMGN). The expanded collaboration will allow both companies to benefit from knowledge-sharing within the field of drug-diagnostic research and development in general, and in relation to companion diagnostic products in particular. The financial details of the agreement were not disclosed.
March 23, 2015
12:10 EDTAMGNTeva migraine drug data positive for Amgen, says Piper Jaffray
Piper Jaffray said the "positive" trial data Teva (TEVA) reported for its anti-CGRP antibody in migraines is another important validation for the class of drugs that is also being worked on by Amgen (AMGN), Eli Lilly (LLY) and Alder Biopharmaceuticals (ALDR). The firm said it thinks Amgen is one of the leaders in CGRP antibody space and reiterated its Overweight rating and $187 price target on Amgen shares.
09:03 EDTAMGNLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
March 20, 2015
09:06 EDTAMGNAmgen submits application for marketing approval for RepathaTM in Japan
Subscribe for More Information
07:41 EDTBAYRY, AMGNAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 19, 2015
15:55 EDTAMGNAmgen injunction bid for Neupogen biosimilar denied, Reuters reports
Subscribe for More Information
15:13 EDTAMGNAmgen denied preliminary injunction for biologics against Novartis, Reuters says
March 17, 2015
16:11 EDTAMGNAmgen to present 10 abstracts from dermatology portfolio
Subscribe for More Information
March 16, 2015
08:52 EDTAMGNAmgen to hold a conference call
Conference call to provide an update from the 73rd Annual Meeting of AAD will be held on March 23 at 3 pm. Webcast Link
08:35 EDTAMGNAmgen to hold a conference call
Executive Vice President of R&D, Sean Harper, discusses Amgen's cardiovascular program, including the Repatha data currently being presented at the American College of Cardiology's Scientific Session & Expo, on a conference call to be held on March 16 at 4 pm. Webcast Link
08:23 EDTAMGNPCSK9 data continues to impress, says Leerink
Subscribe for More Information
06:57 EDTAMGNAmgen clinical data very positive, says RBC Capital
Subscribe for More Information
06:40 EDTAMGNPCSK9 studies show potential improvement in heart health, WSJ says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use